Aleor Gets US FDA Approval For Nystatin And Triamcinolone Acetonide Cream USP
Alembic Pharmaceuticals Limited announced that its joint venture Aleor Dermaceuticals Limited (Aleor) has received final approval from the US Food & Drug Administration (FDA) for its Abbreviated New Drug Application (ANDA) for nystatin and triamcinolone acetonide cream USP, 100,000 units/gram and 1 mg/gram.The approved ANDA is therapeutically equivalent to the reference listed drug product (RLD), nystatin and triamcinolone acetonide cream USP, 100,000 units/gram and 1 mg/gram, of Taro Pharmaceuticals U.S.A. Inc.Nystatin and triamcinolone acetonide cream, USP is indicated for the treatment of cutaneous candidiasis; it has been demonstrated that the nystatin-steroid combination provides greater benefit than the nystatin component alone during the first few days of treatment.Nystatin and triamcinolone acetonide cream, USP has an estimated market size of US$ 19 million for twelve months ending December 2020 according to IQVIA.Alembic has a cumulative total of 139 ANDA approvals (123 final approvals and 16 tentative approvals) from US FDA
Let’s apply Data-Driven Pricing to Your APIs
Sick and tired of always wondering if you are being asked to pay the right price for your APIs? This empowers you with the answers you need to make the right decisions in the Global API market.
Chemxpert Database is one of the biggest and most comprehensive directories of pharma and chemicals, manufacturers, suppliers and information. Provided with current information on prices, demand and transactions, it gives you instant feedback on whether you are buying what is right and at the right time.
Start using market intelligence today and allow yourself to be in control in the API market.
Check it out today and make more informed sourcing decisions!
Learn More!